Literature DB >> 18693718

Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields.

Angel Durán1, Guillermo C Martínez, Manuel Pastor.   

Abstract

Descriptors based on Molecular Interaction Fields (MIF) are highly suitable for drug discovery, but their size (thousands of variables) often limits their application in practice. Here we describe a simple and fast computational method that extracts from a MIF a handful of highly informative points (hot spots) which summarize the most relevant information. The method was specifically developed for drug discovery, is fast, and does not require human supervision, being suitable for its application on very large series of compounds. The quality of the results has been tested by running the method on the ligand structure of a large number of ligand-receptor complexes and then comparing the position of the selected hot spots with actual atoms of the receptor. As an additional test, the hot spots obtained with the novel method were used to obtain GRIND-like molecular descriptors which were compared with the original GRIND. In both cases the results show that the novel method is highly suitable for describing ligand-receptor interactions and compares favorably with other state-of-the-art methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693718     DOI: 10.1021/ci800037t

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  19 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

Review 2.  In silico toxicology: From structure-activity relationships towards deep learning and adverse outcome pathways.

Authors:  Jennifer Hemmerich; Gerhard F Ecker
Journal:  Wiley Interdiscip Rev Comput Mol Sci       Date:  2020-03-31

3.  3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.

Authors:  Huiping Zhao; Elisabetta Moroni; Bin Yan; Giorgio Colombo; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2012-01-01       Impact factor: 4.345

4.  Antiproliferative activity of the Michael adducts of aroylacrylic acids and cyclic amines.

Authors:  Ivan O Juranić; Ana V Tošić; Branka Kolundžija; Branko J Drakulić
Journal:  Mol Divers       Date:  2014-05-30       Impact factor: 2.943

5.  How Far Could We Go with Open Data - A Case Study for TRPV1 Antagonists.

Authors:  Daria A Tsareva; Gerhard F Ecker
Journal:  Mol Inform       Date:  2013-06-18       Impact factor: 4.050

6.  Alignment independent 3D-QSAR, quantum calculations and molecular docking of Mer specific tyrosine kinase inhibitors as anticancer drugs.

Authors:  Fereshteh Shiri; Somayeh Pirhadi; Jahan B Ghasemi
Journal:  Saudi Pharm J       Date:  2015-03-31       Impact factor: 4.330

7.  A 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) Domain.

Authors:  Noreen Akhtar; Ishrat Jabeen
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

8.  Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.

Authors:  Behnam Rasti; Yeganeh Entezari Heravi
Journal:  Res Pharm Sci       Date:  2018-06

9.  2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.

Authors:  Ishrat Jabeen; Penpun Wetwitayaklung; Peter Chiba; Manuel Pastor; Gerhard F Ecker
Journal:  J Comput Aided Mol Des       Date:  2013-02-12       Impact factor: 3.686

10.  Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis.

Authors:  Suleiman A Khan; Seppo Virtanen; Olli P Kallioniemi; Krister Wennerberg; Antti Poso; Samuel Kaski
Journal:  Bioinformatics       Date:  2014-09-01       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.